Slow release fixed dose combination of low doses pramipexole and rasagiline (p2b001) for the treatment of early Parkinson's disease (PD)

被引：0
|
作者：
Olanow, C.
Kieburtz, K.
Livnah, N.
机构：
来源：
MOVEMENT DISORDERS | 2017年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
1329
引用
收藏
页数：1
相关论文
共 10 条
  • [1] A Randomized Trial of a Low-Dose Rasagiline and Pramipexole Combination (P2B001) in Early Parkinson's Disease
    Olanow, C. Warren
    Kieburtz, Karl
    Leinonen, Mika
    Elmer, Lawrence
    Giladi, Nir
    Hauser, Robert A.
    Klepiskaya, Olga S.
    Kreitzman, David L.
    Lew, Mark F.
    Russell, David S.
    Kadosh, Shaul
    Litman, Pninit
    Friedman, Hadas
    Linvah, Nurit
    MOVEMENT DISORDERS, 2017, 32 (05) : 783 - 789
  • [2] P2B001 (Extended Release Pramipexole and Rasagiline): A New Treatment Option in Development for Parkinson's Disease
    Hauser, Robert A.
    Giladi, Nir
    Poewe, Werner
    Brotchie, Jonathan
    Friedman, Hadas
    Oren, Sheila
    Litman, Pninit
    ADVANCES IN THERAPY, 2022, 39 (05) : 1881 - 1894
  • [3] P2B001 (Extended Release Pramipexole and Rasagiline): A New Treatment Option in Development for Parkinson’s Disease
    Robert A. Hauser
    Nir Giladi
    Werner Poewe
    Jonathan Brotchie
    Hadas Friedman
    Sheila Oren
    Pninit Litman
    Advances in Therapy, 2022, 39 : 1881 - 1894
  • [4] Safety and Efficacy of P2B001 (Low Dose Combination of Extended-release Pramipexole and Rasagiline) in Patients with Early Parkinson's Disease: Subgroup Analyses from a Randomized, Controlled
    Falconer, D.
    Litman, P.
    Friedman, H.
    Oren, S.
    Fitter-Attas, C.
    MOVEMENT DISORDERS, 2023, 38 : S21 - S21
  • [5] P2B001 (low dose combination of extended-release pramipexole and rasagiline) versus titrated extended-release pramipexole in the management of early Parkinson's disease: Exploratory findings from a randomized, controlled trial
    Elmer, Lawrence
    Litman, Pninit
    Friedman, Hadas
    Fitzer-Attas, Cheryl
    Oren, Sheila
    NEUROLOGY, 2023, 100 (17)
  • [6] A Randomized Phase 3 Study Comparing P2B001 to its Components (Low-Dose Extended-Release Rasagiline and Pramipexole) and to Optimized Doses of Marketed Extended-Release Pramipexole in Early Parkinson's Disease
    Olanow, C. Warren
    Hauser, Robert A.
    Burdick, Daniel J.
    Dhall, Rohit
    de Marcaida, Joy Antonelle
    Gil, Ramon A.
    Kreitzman, David L.
    Elmer, Lawrence W.
    Mcgarry, Andrew
    Kieburtz, Karl
    MOVEMENT DISORDERS, 2024, 39 (02) : 350 - 359
  • [7] P2B001 significantly reduced risk of daytime sleepiness: results from a randomized controlled phase 3 trial with active pramipexole arm in early Parkinson's disease (PD)
    Kreitzman, David
    Litman, Pninit
    Friedman, Hadas
    Oren, Sheila
    Fitzer-Attas, Cheryl
    NEUROLOGY, 2023, 100 (17)
  • [8] A double-blind 2-year extension of the Parkinson-CONTROL study comparing fixed doses of piribedil (150 mg/day) and bromocriptine (25 mg/day) in early combination with L-dopa in Parkinson's disease (PD)
    Aguilar, M
    Delwaide, P
    Linazasoro, G
    Cesaro, P
    MOVEMENT DISORDERS, 2005, 20 : S77 - S78
  • [9] A double-blind 2-year extension of the Parkinson-CONTROL study comparing fixed doses of piribedil (150 mg/day) and bromocriptine (25 mg/day) in early combination with L-dopa in Parkinson's disease (PD)
    Aguilar, M
    Delwaide, P
    Linazasoro, G
    Cesaro, P
    NEUROLOGY, 2005, 64 (06) : A108 - A108
  • [10] Double-Blind, Placebo-Controlled Fixed-Dose Trial of IPX066, a Novel Carbidopa-Levodopa (CD-LD) Extended-Release Formulation, in Early Parkinson's Disease (APEX-PD Trial)
    Pahwa, Rajesh
    Hauser, Robert
    Jankovic, Joseph
    Nausieda, Paul
    Ellenbogen, Aaron
    Hsu, Ann
    Gupta, Sunell
    NEUROLOGY, 2011, 77 (02) : 199 - 199
1